

## IN THE CLAIMS:

Claims 1, 3, 18, 20, 22, and 47 through 50 are canceled herein without prejudice or disclaimer. Claim 27 has been amended herein. Pending claim 27 and proposed new claim 51 are presented herein. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

1-26. (Canceled).

27. (Twice amended) A method of delivering a nucleic acid of interest to fibroblast-like or macrophage-like cells associated with a synovial cavity, said method comprising:

introducing a recombinant adenovirus comprising the nucleic acid of interest and having a tissue tropism for fibroblast-like or macrophage-like cells associated with a synovial cavity into the synovial cavity;

wherein the recombinant adenovirus's ~~capsid~~ has fiber comprises at least one protein fragment of an adenovirus serotype of subgroup C ~~origin~~ and at least a knob domain of a fiber protein of a second adenovirus ~~16~~ serotype associated therewith, said second adenovirus serotype selected from the group consisting of serotype 11, serotype 16, serotype 35, and serotype 51; and

allowing the recombinant adenovirus to infect the fibroblast-like or macrophage-like cells associated with the synovial cavity.

28-50. (Canceled).

51. (new) The method according to claim 27, wherein said adenovirus serotype of subgroup C is adenovirus serotype 5.